N/A N=16 Acute Exercise Effects in Obese Pregnancy
Pregnancy Complications · Obesity · Pre-Eclampsia
Primary: Oral Glucose Insulin Sensitivity (OGIS) Index — 405.0; 426.0; 418.9 uU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria — 0; 9; 6; 6 Participants
N/A N=14 Evaluation of Carina Microphone Sensitivity and Maximum Stable Gain in Adult Recipients
Hearing Impairment
Primary: Acoustic Sensitivity of Implanted Carina Microphone — -64 dB
N/A N=101 Prostatic Urethral Lift in Subject With Acute Urinary Retention
Acute Urinary Retention · Benign Prostatic Hyperplasia
Primary: Successful Trial Without Catheter Peri-procedurally — 29; 0 Participants
N/A N=26 High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
Prostate Cancer
Primary: Average Mean Dose to 90% of DIL Volume — 13.25 Grays
Phase 1 N=11 Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Hemophilia A · Hemophilia B · Hemophilia A With Inhibitor
Primary: Comparative MarzAA Activity by Dose Level/Stage - AUC0-∞ and AUC0-last — 1390.0; 516.4; 849.4; 1060.0 h*ng/mL
Phase 3 N=3,146 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
Cholera
Primary: Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and B — 9220; 10034 Geometric Mean Titer
Phase 3 N=620 A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Primary: Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase — 31.9; 37.5 Percentage of…
Phase 1 N=6 Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)
Retinal Disease · Retinitis Pigmentosa
Primary: Systemic and Ocular Safety — 0; 0; 1; 0 Participants
Phase 2 N=108 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 81.0; 86.4; 81.8; 72.7 percentage of participants
N/A N=100 A Fib Clinic of the Future Using KardiaPro Platform for Chronic Care of Patients With AF After Ablation Procedure
Atrial Fibrillation
Primary: Time to Atrial Fibrillation Detection — 85.0; 77.6 days
Phase 3 N=211 Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block
Axillary Nerve Block
Primary: Percentage of Participants With Successful Block for Distal Upper Limb Surgeries — 96; 97 Participants
Phase 2 N=50 Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Full Field Visual Evoked Potential (VEP) — 124.8; 126.4; -2.86; -1.50 ms
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
Phase 4 N=46 Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement
Hip Osteoarthritis
Primary: Pain at Rest After Surgery — 3.4; 3.6 score on a scale — p=.770